The trial enrollment milestone, Novo Nordisk supply agreement, and patent allowance are significant derisking events that support the enobosarm thesis. Traders should focus on the Q1 2027 interim DXA readout and Q4 2027 final topline data. The cash runway of $23.9M should fund operations into late CY 2027, though additional capital raises may be needed for Phase 3. Monitor partnership speculation and any safety signals from the fully enrolled PLATEAU study.
Price Chart
Executive Summary
Veru reported fiscal Q3 2026 results. The net loss per share improved to -$0.30 from -$0.50 a year ago, beating the -$0.32 consensus by 6.3%. The key catalysts were operational progress: the Phase 2b PLATEAU trial of enobosarm + semaglutide is now fully enrolled at 239 patients (exceeding the target of 200), the company secured a clinical supply agreement with Novo Nordisk, and received a USPTO Notice of Allowance for a key patent extending protection to at least 2044. The company had $23.9M in cash, down from $27.6M last quarter, funding operations into key interim data readouts.
Key Financial Metrics
Key Facts
- Phase 2b PLATEAU trial fully enrolled with 239 patients, exceeding the 200-patient target.
- Interim analysis (DXA at 32 weeks) on track for calendar Q1 2027; final topline data expected Q4 2027.
- Clinical supply agreement executed with Novo Nordisk for the Phase 2b PLATEAU trial.
- USPTO issued Notice of Allowance for key U.S. patent covering enobosarm + semaglutide; patent protection expected until at least October 2044.
- Net loss per share was -$0.30, improved from -$0.50 in the prior-year period and beating consensus of -$0.32.
- Cash, cash equivalents, and restricted cash were $23.9M as of June 30, 2026, down from $27.6M as of March 31, 2026, but up from $15.8M as of September 30, 2025.
Financial Impact
EPS beat consensus by +6.3% (-$0.30 actual vs -$0.32 est). No revenue reported (pre-revenue biotech). Cash burn of $3.7M in the quarter, with $23.9M on hand.
Risk Factors
- Interim or final Phase 2b data may fail to meet endpoints, destroying the pipeline thesis.
- Novo Nordisk can terminate the clinical supply agreement for convenience on 60 days notice.
- Cash burn will continue; additional equity financing will likely be required before an approved product generates revenue.
- Regulatory pathway for enobosarm is uncertain; FDA may require additional Phase 3 studies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341187 |
| Document: d123580d8k.htm | 0001193125-26-341187 |
| Document: 0001193125-26-341187-index-headers.html | 0001193125-26-341187 |
| Document: 0001193125-26-341187-index.html | 0001193125-26-341187 |
| Document: 0001193125-26-341187.txt | 0001193125-26-341187 |
| 8-K Data (Synthetic) | 0001193125-26-341187 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $2.77 $2.79 | ▲ +0.72% | ▲ +1.04% | $2.28 (−17.69%) |
Aug 10, 2026 11w ago | Press Release | $2.77 $2.79 | ▲ +0.72% | ▲ +1.04% | $2.28 (−17.69%) |
Jul 2, 2026 16w ago | 8-K / 424B5 | $3.06 $2.83 | ▲ +7.52% | ▲ +8.39% | $2.28 (+25.49%) |
Jun 4, 2026 20w ago | 8-K | $4.23 $3.40 | ▼ −19.62% | ▼ −17.02% | $2.28 (−46.10%) |
May 13, 2026 23w ago | 8-K | $2.26 $2.09 | ▼ −7.52% | ▼ −8.30% | $2.28 (+0.88%) |
May 13, 2026 23w ago | Press Release | $2.26 $2.09 | ▼ −7.52% | ▼ −8.30% | $2.28 (+0.88%) |
Apr 7, 2026 29w ago | S-3 | $2.55 $2.43 | ▲ +4.71% | ▲ +5.28% | $2.28 (+10.59%) |
Apr 7, 2026 29w ago | S-3 | $2.55 $2.43 | ▲ +4.71% | ▲ +5.28% | $2.28 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers